Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1016/S2213-8587(19)30158-5
- Subjects: SÍNDROME CORONARIANA AGUDA; DIABETES MELLITUS; ANTICORPOS MONOCLONAIS; DOENÇAS CARDIOVASCULARES; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Lancet diabetes & endocrinology
- ISSN: 2213-8587
- Volume/Número/Paginação/Ano: v. 7, n. 8, p. 618-628, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
RAY, Kausik K et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, v. 7, n. 8, p. 618-628, 2019Tradução . . Disponível em: https://doi.org/10.1016/S2213-8587(19)30158-5. Acesso em: 16 maio 2024. -
APA
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-dinet, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, 7( 8), 618-628. doi:10.1016/S2213-8587(19)30158-5 -
NLM
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5 -
Vancouver
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1016/S2213-8587(19)30158-5 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
